No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BIOR240816P1000
- 0.34
- 0.000.00%
15min DelayClose Jul 19 16:00 ET
0.34High0.34Low
0.34Open0.34Pre Close1 Volume0 Open Interest1.00Strike Price34.00Turnover75.34%IV0.00%PremiumAug 16, 2024Expiry Date0.34Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9980Delta0.3932Gamma1.94Leverage Ratio0.0000Theta0.0000Rho-1.94Eff Leverage0.0000Vega
Intraday
- 5D
- Daily
News
Biora Therapeutics Advances Ulcerative Colitis Treatment With BT-600 Trial Success
Express News | Biora Therapeutics Announces Supplemental Data From Phase 1 Clinical Trial of BT-600 as Presented at Kol Event
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results From Phase 1 Clinical Trial of BT-600 on July 17, 2024
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday,
Biora Therapeutics Reports Positive Data For Trial Of BT-600 In Ulcerative Colitis
Express News | Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
Express News | Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Comments
$Biora Therapeutics(BIOR.US$
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
$Biora Therapeutics (BIOR.US)$ anyone know why sudden rise?
$Biora Therapeutics(BIOR.US$
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
$Biora Therapeutics(BIOR.US$ Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
Read more